PD 0299685

Drug Profile

PD 0299685

Alternative Names: PD-299,685; PF-299685

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Analgesics; Sleep disorder therapies
  • Mechanism of Action Calcium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insomnia; Interstitial cystitis; Vasomotor symptoms

Most Recent Events

  • 27 Sep 2010 Discontinued - Phase-II for Interstitial cystitis in USA (PO)
  • 29 Jan 2010 Pfizer completes phase-II clinical trial in Interstitial cystitis in USA (PO)
  • 30 Sep 2008 Phase-II clinical trials in Interstitial cystitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top